ClinicalTrials.gg
Not yet recruitingNCT07487792Updated Nov 18, 2026

Feasibility of Imaging Breast Implants With a Transmission-based Microwave Scanner

An interventional study of WVI-MIS-03-2025 in Breast - Female, sponsored by University of Calgary. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Calgary · Not applicable, Interventional, and Other

How we know

Updated Nov 18, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to assess whether microwave scans can depict the presence of implants in the breast in women with existing breast implants that were surgically placed at least 6 months ago. The main questions it aims to answer are:

  1. Can a microwave imaging device effectively scan a breast containing implants?
  2. Can the presence of implants be identified in a microwave scan?
  3. Can the microwave scans of the left and right breasts be compared to assess whether similarity is observed?
Read the detailed description

Breast implants are consistently one of the top 5 cosmetic procedures performed each year in North America. The Food and Drug Administration (FDA) cites a 10% risk of rupture over 10 years (1% cumulative per annum risk of device rupture).

Rupture refers to disruption in the integrity of the implant, and is typically age-related deterioration where age in this context refer to the implant. Rupture in saline implants is detected with rapid change in breast size. With silicone implants, rupture is much more challenging to detect as it is rare to have a completely collapsed implant shell.

Current recommendations for surveillance of breast implants include Magnetic Resonance Imaging (MRI) or ultrasound within 5-6 years of surgery for the initial test, then every 2-3 years. The guideline initially included only MRI but was adjusted in 2022 to include ultrasound. Patient adherence to guidelines with only MRI was very low (less than 5%), which is postulated to relate to the expense, discomfort, and inaccessibility of MRI. Mammography is a frequently used breast imaging method. However, the majority of women with implants are too young for breast screening programs that involve regular mammograms. Also, the implant is displaced during mammography to focus on the breast tissues. Finally, mammography involves exposure to x-rays, limiting regular scans in women too young for screening.

Therefore, there is a need to regularly inspect silicone implants for silent rupture. An imaging approach that is low-cost, available at point-of-care, easy to use, and reliable (i.e. sensitive to implant rupture) would be a valuable tool for plastic surgery clinics.

Microwave imaging has been proposed as a low-cost and comfortable approach to breast imaging that can be performed at point of care. This approach to imaging is low power, so no tissue heating occurs and there are no other side effects. Therefore, microwave imaging is suited to in-clinic, ongoing monitoring of the breast.

10 women with breast implants will be recruited from plastic surgery clinics. This includes women with breast implants that were surgically placed at least 6 months prior and are asymptomatic for implant rupture, as well as women who have implants with a confirmed rupture. Study participants will be scanned with the microwave imaging system. Three scans of each breast will be collected in each of the Craniocaudal (CC) and Mediolateral Oblique (MLO) views.

The breast positioning will be adjusted between scans to maximize the presentation of the implant in the imaging volume. The images will be analyzed to identify the implants, as the implants have different properties when compared to healthy breast tissues.

02

Conditions studied

  • Breast - Female

Keywords

  • women
  • breast implant
03

In context

Lead sponsor

University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with breast implants placed at least 6 months prior who are asymptomatic for implant rupture as well as those with known implant rupture
  • Female
  • Minimum of 18 years of age
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Women who are currently pregnant or breastfeeding
  • Women with active breast infections
  • Women with nipple piercings (unless removed prior to scanning)
  • Women with implanted electronic device
  • Women with physical limitations that prevent them from placing their breasts inside the scanner
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    A single arm study to determine feasibility of imaging breast implants

    WVI-MIS-03-2025

    Device: WVI-MIS-03-2025

Interventions

  • DeviceWVI-MIS-03-2025

    Microwave scans

06

What researchers measure

Primary outcomes

  1. Measurement of regions of interest in microwave images

    Images of both breasts will be created. Regions of interest corresponding to the breast implants will be identified using the electrical properties. The size of these regions will be calculated.

    Time frame: 12 months

Secondary outcomes

  1. Comparison of total area in implant in microwave image with known physical size

    The total area corresponding to the breast implant in the microwave images will be calculated and compared with the known implant size.

    Time frame: 12 months

  2. Compare microwave scans of the left and right breast

    The properties and size of the region corresponding to the implant will be compared between right and left breasts.

    Time frame: 12 months

07

Study locations

1 site
  • Demsey Plastic Surgery Clinic
    Calgary, Alberta T3H 3K8, Canada
08

References and documents

Publications

  • Mojabi P, Tsang RY, Docktor B, Deutscher D, Garland A, Mahsin M, Bourqui J, Fear E. Feasibility of tumor detection with a transmission-based microwave imaging system. Med Phys. 2025 Sep;52(9):e18080. doi: 10.1002/mp.18080. PubMed 40940299 ↗
  • Mojabi P, Bourqui J, Docktor BJ, Tsang RY, Fear E. Assessment of Breast Composition With a Transmission-Based Microwave Imaging System. IEEE Trans Biomed Eng. 2026 Jan;73(1):451-461. doi: 10.1109/TBME.2025.3584669. PubMed 40587354 ↗
  • Mojabi P, Tsang RY, Docktor BJ, Deutscher D, Garland A, Lasemiimeni Z, Bourqui J, Fear E. Point-of-Care Breast Imaging for Monitoring Neoadjuvant Treatment: Case Studies With Transmission-Based Microwave Imaging. IEEE Trans Biomed Eng. 2026 Mar;73(3):1181-1190. doi: 10.1109/TBME.2025.3599516. PubMed 40815587 ↗
  • Smith, K., et al. "Microwave Imaging of the Breast: Consistency of Measurements Over Time." IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology, vol. 6, no. 1, 2022, pp. 61-67, https://doi.org/10.1109/JERM.2021.3099014.
  • Butterworth, Carina M., et al. "Quantifying Consistency of Microwave Breast Imaging: Laser Scanning for Assessing Breast Volume and Shape." IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology, vol. 9, no. 3, 2025, pp. 335-43, https://doi.org/10.1109/JERM.2025.3531693.
  • Mojabi P, Bourqui J, Lasemiimeni Z, Grewal B, Fear E. Microwave Imaging for Breast Cancer Detection: Performance Assessment of a Next-Generation Transmission System. IEEE Trans Biomed Eng. 2025 Jun;72(6):1787-1799. doi: 10.1109/TBME.2024.3521410. PubMed 40031671 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 15, 2026→Dec 1, 2026
Nov 18, 2026
Primary completion
Dec 15, 2026→Dec 30, 2026
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Sep 15, 2026→Dec 1, 2026
    Primary completion Dec 15, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07487792
Collaborators
Wave View Imaging Inc.
Responsible party
Elise Fear (Professor, University of Calgary) — Principal investigator
First posted
Mar 23, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Anita Garland
Contact
anita.garland@ucalgary.ca
403-703-1664
Elise Fear
Contact
fear@ucalgary.ca
403-210-5413

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion